MDA (Medical Devices Agency) promises tough action to safeguard EU device regulation
This article was originally published in Clinica
Executive Summary
The Medical Devices Agency is tackling head on the main focus of the criticism levelled at the European medical device regulations, the notified bodies (third-party assessors of devices), by taking draconian action where it identifies areas of concern. In the year 2001-02, it suspended a number of individual assessors while they were retrained and prevented certain notified bodies from dealing with some types of products or from taking on new customers until the problems had been fully addressed.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.